1
|
Pernas S, Goel S, Harrison BT, Hu J, Johnson N, Regan M, Chichester LA, Nakhlis F, Schlosnagle EJ, Winship G, Guerriero JL, Parsons H, Mittendorf EA, Overmoyer B. Abstract PD3-08: Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd3-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inflammatory breast cancer (IBC) is an aggressive form of breast cancer that remains relatively understudied. We examined the efficacy of neoadjuvant dual-HER2 blockade (trastuzumab (H) and pertuzumab (P)) combined with paclitaxel (T) in HER2+ IBC, including a planned analysis to elucidate associations between the tumor immune microenvironment profile and response to therapy.
Methods: An IRB-approved, single-arm phase II trial for patients (pts) with newly diagnosed HER2+ IBC was conducted. Pts had a pre-treatment biopsy of the affected breast (D1) followed by a loading dose of HP. A second biopsy was performed 1 week (wk) later (D8), when T (80mg/m2/wk x 16 wks) was added to HP. Responding pts underwent modified radical mastectomy (MRM) where residual disease was collected. The primary objective was to determine the rate of pathologic complete response (pCR) defined as ypT0/isN0. Residual Cancer Burden (RCB) was also determined. Tumor specimens from D1, D8 and MRM were assessed for disease cellularity and scored for percentage of tumor infiltrating lymphocytes (TILs): low=0-10%, intermediate=11-59%, high>60%. RNA-sequencing was performed on tumor tissue from D1 and D8 to explore the impact of short-term HP treatment on the tumor transcriptomic profile and to identify potential predictors of pCR.
Results: 23 pts with HER2+ IBC were enrolled between 8/2013-6/2017. Mean age was 48 years (range 32-74); 11 pts (48%) had estrogen and progesterone receptor (ER/PR) negative disease. Matched tumor biopsies (D1, D8) were obtained in all 23 pts; 21 underwent MRM; 1 was lost to follow-up and 1 had disease progression. In the intent to treat analysis, 10/23 (43%) pts achieved a pCR and 7 (30%) had RCB-1. Ten of the 22 evaluable pts achieved a pCR (45.5%). TILs were evaluable in 20/23 (87%) matched tumor biopsies (D1, D8). Among the D1 biopsy specimens: 19 (95%) had low levels, 2 (10%) had intermediate levels, and none had high levels. When D1 TIL levels were compared with D8 levels, 3(15%) had an increase in TILs, 16(80%) had no change in TIL levels, and 1(5%) had a decrease in the level of TILs. Both samples with intermediate levels and 2 of 3 samples with high levels of TILs on D1 and D8 were seen in ER/PR negative disease. An evaluation of biopsy specimens associated with subsequent pCR using GO enrichment analysis from the RNA-Seq data showed significant upregulation of several immune-process related gene expression signatures both at D1 and D8 (e.g. antigen processing and presentation, TCR signaling, NK cell cytotoxicity, p-value: 2.99E-48 to 1.39E-16) when compared with those associated with residual disease at the time of MRM. Across the entire cohort, D8 biopsies showed evidence of upregulated anti-tumor immunity compared to D1 biopsies (p-value: 9.57E-06 to 0.012). Notably, this change from D1 to D8 was largely restricted to tumors that achieved a pCR.
Conclusion: THP for 16 weeks was a highly effective treatment for HER2+ IBC. Immune activation as determined by gene expression signatures predicted pCR, and moreover upregulation of anti-tumor immunity after 1 wk of HP might further predict a complete pathologic response to therapy. ClinicalTrials.gov identifier: NCT01796197
Citation Format: Pernas S, Goel S, Harrison BT, Hu J, Johnson N, Regan M, Chichester LA, Nakhlis F, Schlosnagle EJ, Winship G, Guerriero JL, Parsons H, Mittendorf EA, Overmoyer B. Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD3-08.
Collapse
Affiliation(s)
- S Pernas
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - S Goel
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - BT Harrison
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - J Hu
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - N Johnson
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - M Regan
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - LA Chichester
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - F Nakhlis
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - EJ Schlosnagle
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - G Winship
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - JL Guerriero
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - H Parsons
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - EA Mittendorf
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| | - B Overmoyer
- Dana Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA
| |
Collapse
|
2
|
Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Abstract P3-05-05: Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p3-05-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
While tumor-associated macrophages (TAMs) often have net pro-tumor effects, their embedded location and their untapped potential provide impetus to the discovery of strategies to turn them against tumors. We recently reported that a first in class selective class IIa HDAC inhibitor (TMP195) influenced human monocyte responses to colony stimulating factors CSF-1 and CSF-2 in vitro. Here, we utilize a macrophage-dependent autochthonous mouse model of breast cancer to demonstrate that in vivo TMP195 treatment alters the tumor microenvironment and reduces tumor burden and pulmonary metastases through macrophage modulation. TMP195 induces recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors. Furthermore, combining TMP195 with chemotherapy regimens or T-cell checkpoint blockade in this model significantly enhances the durability of tumor reduction. These data introduce class IIa HDAC inhibition as a novel means to harness the anti-tumor potential of macrophages to enhance cancer therapy.
Citation Format: Guerriero JL, Sotayo A, Ponichtera HE, Castrillon JA, Pourzia AL, Schad S, Johnson SF, Carrasco RD, Lazo S, Bronson RT, Davis SP, Lobera M, Nolan MA, Letai A. Class IIa HDAC inhibition promotes an anti-tumor macrophage phenotype that induces breast tumor regression and inhibits metastasis [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P3-05-05.
Collapse
Affiliation(s)
- JL Guerriero
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - A Sotayo
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - HE Ponichtera
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - JA Castrillon
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - AL Pourzia
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - S Schad
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - SF Johnson
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - RD Carrasco
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - S Lazo
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - RT Bronson
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - SP Davis
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - M Lobera
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - MA Nolan
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| | - A Letai
- Dana-Farber Cancer Institute, Boston, MA; Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA; GlaxoSmithKline, Cambridge, MA
| |
Collapse
|
3
|
Touzeau C, Ryan J, Guerriero J, Moreau P, Chonghaile TN, Le Gouill S, Richardson P, Anderson K, Amiot M, Letai A. BH3 profiling identifies heterogeneous dependency on Bcl-2 family members in multiple myeloma and predicts sensitivity to BH3 mimetics. Leukemia 2015; 30:761-4. [PMID: 26174630 PMCID: PMC4714955 DOI: 10.1038/leu.2015.184] [Citation(s) in RCA: 109] [Impact Index Per Article: 12.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- C Touzeau
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.,Department of Hematology, University hospital, Nantes, France.,INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France
| | - J Ryan
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - J Guerriero
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - P Moreau
- Department of Hematology, University hospital, Nantes, France.,INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France
| | - T N Chonghaile
- Conway Institute of Biomolecular and Biomedical Research, Dublin, Ireland
| | - S Le Gouill
- Department of Hematology, University hospital, Nantes, France.,INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France
| | - P Richardson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - K Anderson
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - M Amiot
- INSERM UMR892, CNRS UMR6299, University of Nantes, Nantes, France
| | - A Letai
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| |
Collapse
|
4
|
Baker R, Szudy B, Guerriero J. Working with labor unions. What occupational health nurses need to know. AAOHN J 2000; 48:563-70; quiz 571-2. [PMID: 11760284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
1. The work of many occupational health nurses involves interaction with labor unions in a range of settings, yet little training is provided to understand unions and their role. 2. Understanding the structure and function of unions can help nurses work more effectively in collaboration with labor toward the common goal of reducing workplace injury and illness. 3. Nurses need to educate union members and leadership to better understand the full range of skills and responsibilities of occupational health nurses.
Collapse
Affiliation(s)
- R Baker
- Labor Occupational Health Program, Center for Occupational and Environmental Health, School of Public Health, University of California, Berkeley, USA
| | | | | |
Collapse
|
5
|
Guerriero J. Nursing students can expect better occupational and environmental health training. Imprint 1994; 41:77-9. [PMID: 7927426] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
6
|
Lester D, Decker J, Eisenberg RJ, Ecker C, Guerriero J, Mielish C. Association between whirling responses on psychological tests and suicidal preoccupation. Percept Mot Skills 1990; 71:1105. [PMID: 2087363 DOI: 10.2466/pms.1990.71.3f.1105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Using a different test (number of spinning phrases chosen and the Beck Depression Inventory) and sample (201 undergraduates), data confirmed an observation by Thomas and Duzynski, as chosen spinning phrases were correlated with prior suicidal ideation. However, the numbers of phrases were not correlated with depression scores.
Collapse
Affiliation(s)
- D Lester
- Psychology Program, Richard Stockton State College, Pomona, NJ 08240
| | | | | | | | | | | |
Collapse
|
7
|
Guerriero J. Experience from the Occupational Health Clinic at San Francisco. Toxicol Ind Health 1989; 5:57-9; discussion 79-84. [PMID: 2763322 DOI: 10.1177/074823378900500407] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- J Guerriero
- Occupational Health Clinic, San Francisco General Hospital
| |
Collapse
|
8
|
Orris P, Kennedy MJ, Guerriero J, Hessl SM, Hryhorczuk DO, Hoffman D. Activities of an employer independent Occupational Medicine Clinic, Cook County Hospital, 1979-1981. Am J Public Health 1982; 72:1165-7. [PMID: 7114343 PMCID: PMC1650185 DOI: 10.2105/ajph.72.10.1165] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
In July 1976, Cook County Hospital, a 1,363-bed general public hospital in Chicago, Illinois, established a hospital-funded Occupational Medicine Clinic. A review was made of the clinic records of the 486 new patients evaluated at the clinic from July 1979 to June 1981. Information is presented concerning age, ethnic origin, sex, union representation, referral sources, reason for the referral, number and type of toxic exposure, diagnosis, occupational relationship of the disease, and disposition.
Collapse
|